Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7852144 | 0.88 | FAAH (0.51) | ALDH1A1KDM4ESMN1; SMN2HTTLMNA | |
| SCHEMBL2661873 | 0.86 | PRMT1 (0.47) | ALDH1A1KDM4EHTTLMNAMAPT | |
| SCHEMBL266762 | 0.85 | GLS (0.51) | ALDH1A1KDM4EHTT | |
| SCHEMBL4466600 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL6301408 | 0.83 | HRH3 (0.59) | ALDH1A1KDM4ESMN1; SMN2ALOX15HTT | |
| SCHEMBL7475308 | 0.83 | ALDH1A1 (0.70) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL8440690 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL3948130 | 0.82 | LMNA (0.55) | ALDH1A1KDM4ESMN1; SMN2HTTLMNA | |
| SCHEMBL654393 | 0.81 | ALDH1A1 (0.73) | ALDH1A1KDM4ESMN1; SMN2HTTGAA | |
| SCHEMBL2662019 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4EPOLBSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194410-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH AS (DK) | 2006-01-18 | — | — | EP | disclosed |
| US-6936613-B2 | Benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S (DK) | 2005-08-30 | — | — | US | disclosed |
| CN-1167686-C | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | О | 2004-09-22 | — | — | CN | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ALDH1A1 977/4885KDM4E 851/4885POLB 4499/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | ALDH1A1 1345/4885KDM4E 834/4885POLB 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.